Get the Stockscreener App
208.05
0.45%
-0.93
After Hours:
208.05
Overview
News
Price History
Option Chain
Financials
Why RMD Down?
Discussions
Forecast
Stock Split
Dividend History
Resmed Inc stock is traded at $208.05, with a volume of 1.10M.
It is down -0.45% in the last 24 hours and down -6.30% over the past month.
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks, and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with aging populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two-thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan, and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor, and payer in the out-of-hospital setting.
See More
Previous Close:
$208.98
Open:
$208.98
24h Volume:
1.10M
Relative Volume:
0.96
Market Cap:
$30.18B
Revenue:
$5.54B
Net Income/Loss:
$1.52B
P/E Ratio:
20.06
EPS:
10.3734
Net Cash Flow:
$1.74B
1W Performance:
+3.06%
1M Performance:
-6.30%
6M Performance:
-17.03%
1Y Performance:
-15.25%
1-Day Range:
$207.25
$211.06
1-Week Range:
$200.25
$211.74
52-Week Range:
$198.61
$293.81
Resmed Inc Stock (RMD) Company Profile
Name
Resmed Inc
Sector
Industry
Phone
(858) 746-2400
Address
9001 SPECTRUM CENTER BLVD., SAN DIEGO, CA
Compare RMD vs ISRG, BDX, ALC, MDLN
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
RMD
Resmed Inc
|
208.05 | 30.31B | 5.54B | 1.52B | 1.74B | 10.37 |
ISRG
Intuitive Surgical Inc
|
438.10 | 155.76B | 10.58B | 3.00B | 2.83B | 8.2437 |
BDX
Becton Dickinson Co
|
147.63 | 40.30B | 21.37B | 1.41B | 3.07B | 3.9437 |
ALC
Alcon Inc
|
67.78 | 33.13B | 10.63B | 819.00M | 1.59B | 1.6577 |
MDLN
Medline Inc
|
37.01 | 31.37B | 29.14B | 1.07B | 1.05B | 1.1956 |
Resmed Inc Stock (RMD) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-15-26 | Initiated | JP Morgan | Overweight |
| Dec-16-25 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Sep-18-25 | Initiated | Citigroup | Buy |
| Sep-02-25 | Upgrade | CLSA | Hold → Outperform |
| Jul-15-25 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Mar-19-25 | Initiated | Morgan Stanley | Overweight |
| Jan-16-25 | Initiated | Goldman | Buy |
| Jan-10-25 | Initiated | Piper Sandler | Neutral |
| Dec-13-24 | Initiated | Stifel | Hold |
| Sep-24-24 | Initiated | Robert W. Baird | Outperform |
| Sep-18-24 | Downgrade | Wolfe Research | Peer Perform → Underperform |
| Sep-04-24 | Downgrade | Needham | Buy → Hold |
| Jun-25-24 | Downgrade | Oppenheimer | Outperform → Perform |
| Jun-24-24 | Downgrade | Citigroup | Buy → Neutral |
| Feb-06-24 | Resumed | KeyBanc Capital Markets | Overweight |
| Oct-27-23 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Oct-12-23 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Oct-09-23 | Upgrade | JP Morgan | Neutral → Overweight |
| Sep-29-23 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| Sep-06-23 | Upgrade | Needham | Hold → Buy |
| Sep-05-23 | Downgrade | UBS | Buy → Neutral |
| Aug-01-23 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| May-23-23 | Initiated | UBS | Buy |
| Apr-14-23 | Initiated | Mizuho | Buy |
| Jan-17-23 | Upgrade | JP Morgan | Neutral → Overweight |
| Oct-28-22 | Downgrade | Citigroup | Buy → Neutral |
| Oct-20-22 | Upgrade | BofA Securities | Neutral → Buy |
| Oct-12-22 | Initiated | Jefferies | Hold |
| Sep-08-22 | Upgrade | Citigroup | Neutral → Buy |
| Aug-15-22 | Downgrade | CLSA | Buy → Outperform |
| Aug-12-22 | Downgrade | Citigroup | Buy → Neutral |
| Aug-12-22 | Downgrade | JP Morgan | Overweight → Neutral |
| Aug-12-22 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Jun-06-22 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Apr-06-22 | Initiated | Wolfe Research | Outperform |
| Jan-31-22 | Upgrade | Citigroup | Neutral → Buy |
| Jan-31-22 | Upgrade | Goldman | Neutral → Buy |
| Jan-28-22 | Upgrade | RBC Capital Mkts | Underperform → Sector Perform |
| Jan-24-22 | Upgrade | BofA Securities | Underperform → Neutral |
| Jan-24-22 | Upgrade | JP Morgan | Neutral → Overweight |
| Jan-13-22 | Upgrade | CLSA | Outperform → Buy |
| Jan-13-22 | Upgrade | Robert W. Baird | Neutral → Outperform |
| Dec-21-21 | Upgrade | KeyBanc Capital Markets | Sector Weight → Overweight |
| Dec-06-21 | Upgrade | Macquarie | Neutral → Outperform |
| Oct-22-21 | Upgrade | CLSA | Underperform → Outperform |
| Aug-02-21 | Downgrade | CLSA | Outperform → Sell |
| Aug-02-21 | Downgrade | Needham | Buy → Hold |
| Jul-28-21 | Upgrade | Jefferies | Underperform → Hold |
| Jul-26-21 | Downgrade | JP Morgan | Overweight → Neutral |
| Jul-14-21 | Initiated | RBC Capital Mkts | Underperform |
| Jun-28-21 | Downgrade | Citigroup | Buy → Neutral |
| Jun-22-21 | Upgrade | Macquarie | Neutral → Outperform |
| Jun-22-21 | Initiated | Robert W. Baird | Neutral |
| Jun-21-21 | Reiterated | Needham | Buy |
| Jun-16-21 | Downgrade | BofA Securities | Neutral → Underperform |
| Jun-09-21 | Upgrade | CLSA | Sell → Outperform |
| May-21-21 | Upgrade | JP Morgan | Neutral → Overweight |
| May-11-21 | Upgrade | Citigroup | Neutral → Buy |
| Apr-30-21 | Downgrade | Citigroup | Buy → Neutral |
| Mar-16-21 | Upgrade | Needham | Hold → Buy |
| Nov-02-20 | Upgrade | UBS | Neutral → Buy |
| Oct-30-20 | Upgrade | JP Morgan | Underweight → Neutral |
| Oct-27-20 | Upgrade | BofA Securities | Underperform → Neutral |
| Aug-07-20 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Jun-17-20 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| May-01-20 | Downgrade | JP Morgan | Neutral → Underweight |
| May-01-20 | Upgrade | Oppenheimer | Perform → Outperform |
| Feb-18-20 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Feb-03-20 | Initiated | CLSA | Underperform |
| Jan-31-20 | Downgrade | UBS | Buy → Neutral |
| Jan-10-20 | Initiated | Oppenheimer | Perform |
| Nov-22-19 | Initiated | KeyBanc Capital Markets | Sector Weight |
| Jul-29-19 | Upgrade | UBS | Neutral → Buy |
| Jul-16-19 | Downgrade | UBS | Buy → Neutral |
| May-06-19 | Upgrade | UBS | Neutral → Buy |
| Apr-18-19 | Upgrade | JP Morgan | Underweight → Neutral |
| Jan-25-19 | Downgrade | Goldman | Buy → Neutral |
| Jan-25-19 | Downgrade | JP Morgan | Neutral → Underweight |
| Oct-26-18 | Upgrade | Credit Suisse | Neutral → Outperform |
| Jul-02-18 | Initiated | Goldman | Buy |
View All
Resmed Inc Stock (RMD) Latest News
ResMed Inc. stock (US7611521078): sleep-apnea specialist in focus after latest earnings update - AD HOC NEWS
ResMed Stock Near 52-Week Low Despite 21% EPS Growth: Here’s What the GLP-1 Data Actually Shows - TIKR.com
Do Wall Street Analysts Like ResMed Stock? - Barchart.com
ResMed Inc. (RMD) Stock Analysis: Robust Growth Potential Amidst Healthcare Innovations - DirectorsTalk Interviews
Life Cycle Investment Partners Ltd Invests $31.23 Million in ResMed Inc. $RMD - MarketBeat
Catalyst Funds Management Pty Ltd Sells 8,400 Shares of ResMed Inc. $RMD - MarketBeat
ResMed Inc. (NYSE:RMD) Given Average Rating of "Moderate Buy" by Analysts - MarketBeat
Cumberland Partners Ltd Purchases 8,000 Shares of ResMed Inc. $RMD - MarketBeat
Why ResMed Sleep Tech Push Is Turning Heads? - Kalkine Media
Thrivent Financial for Lutherans Buys 11,481 Shares of ResMed Inc. $RMD - MarketBeat
Is the options market predicting a spike in ResMed stock? - MSN
RMD Stock Price, Quote & Chart | RESMED INC (NYSE:RMD) - ChartMill
ResMed Inc stock (US75102W1036): sleep apnea specialist draws attention after latest options moves - AD HOC NEWS
How ResMed–Oura Wearable Sleep Data Partnership Could Reshape ResMed's (RMD) Clinical Ecosystem - Sahm
ResMed stock (US7611521078): sleep apnea specialist in focus after latest earnings - AD HOC NEWS
How Investors Are Reacting To ResMed (RMD) Linking Oura Ring Wearables To Clinical Sleep Care - Yahoo Finance
ResMed Inc. stock rises Wednesday, still underperforms market - MarketWatch
Is the Options Market Predicting a Spike in ResMed Stock? - Zacks Investment Research
ResMed stock (US7611521078): sleep apnea specialist in focus after latest quarterly results - AD HOC NEWS
ResMed (RMD) Valuation Check As Oura Sleep Health Collaboration Aims To Expand Sleep Apnea Care Access - Yahoo Finance
5,006 Shares in ResMed Inc. $RMD Acquired by North Dakota State Investment Board - MarketBeat
Resmed, Oura partner on sleep health education, care - MassDevice
Resmed (RMD) Teams Up with Oura to Enhance Sleep Health Educatio - GuruFocus
ResMed Rises After Partnership With Oura to Expand Sleep Health Education, Care Pathways - Moomoo
ResMed Inc. stock rises Tuesday, outperforms market - MarketWatch
Resmed Announces Participation in the 46th Annual William Blair Growth Stock Conference - Caledonian Record
ResMed Targets Circadian Data With New Wearable Trial: What Investors Should Watch - TipRanks
Resmed and ŌURA Partner to Expand Access to Sleep Health Education and Care - marketscreener.com
Oura Ring now links sleep changes to Resmed sleep resources - Stock Titan
ResMed Inc stock (US75102W1036): sleep apnea specialist in focus after fresh institutional buying - AD HOC NEWS
ResMed Inc. stock (US7611521078): Earnings beat and dividend lift focus - AD HOC NEWS
Watchman Group, Inc.'s ResMed Inc(RMD) Holding History - GuruFocus
Why this fallen ASX 200 blue chip could be a strong buy - MSN
ResMed Inc. stock rises Monday, outperforms market - MarketWatch
Should you continue to hold Resmed stock in your portfolio? - MSN
Integrated Investment Consultants LLC Invests $1.34 Million in ResMed Inc. $RMD - MarketBeat
Passumpsic Savings Bank Purchases New Stake in ResMed Inc. $RMD - MarketBeat
ResMed Inc. (RMD) Stock Analysis: Exploring a 34% Potential Upside in the Healthcare Sector - DirectorsTalk Interviews
ResMed Inc. stock (US7611521078): dividend in focus after solid Q3 results - AD HOC NEWS
Why are ResMed shares lagging if the business keeps compounding? - MSN
Stephens Investment Management Group LLC Decreases Position in ResMed Inc. $RMD - MarketBeat
ResMed Inc. stock falls Friday, underperforms market - MSN
With Strong Cash Flow, ResMed Stock Poised to Rise? - Trefis
Strong Cash Yield: Is ResMed Stock A Buy? - Trefis
ResMed Inc stock (US75102W1036): Noctrix deal, dividend and shifting sentiment put sleep-therapy spe - AD HOC NEWS
Arbejdsmarkedets Tillaegspension Makes New Investment in ResMed Inc. $RMD - MarketBeat
ResMed Inc stock (AU000000RMD6): Noctrix deal and market cap slide in focus - AD HOC NEWS
Needham reiterates Hold on ResMed stock on Noctrix acquisition By Investing.com - Investing.com South Africa
Needham reiterates Hold on ResMed stock on Noctrix acquisition - Investing.com
ResMed Inc. stock (US7611521078): earnings beat, dividend and softer 2026 share price - AD HOC NEWS
Bank Julius Baer & Co. Ltd Zurich Lowers Stock Position in ResMed Inc. $RMD - MarketBeat
Resmed Inc Stock (RMD) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.24%
0.09%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):